Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Travere Therapeutics Inc
(NQ:
TVTX
)
5.260
-0.130 (-2.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,220,072
Open
5.400
Bid (Size)
5.160 (50)
Ask (Size)
5.610 (1)
Prev. Close
5.390
Today's Range
5.210 - 5.555
52wk Range
5.120 - 22.75
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
April 17, 2024
Via
Benzinga
Performance
YTD
-44.98%
-44.98%
1 Month
-31.42%
-31.42%
3 Month
-38.84%
-38.84%
6 Month
-22.65%
-22.65%
1 Year
-74.14%
-74.14%
More News
Read More
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
March 13, 2024
Via
Benzinga
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
February 16, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Earnings Preview For Travere Therapeutics
February 14, 2024
Via
Benzinga
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
February 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
January 18, 2024
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
December 15, 2023
Via
Benzinga
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
Via
Benzinga
Exposures
Product Safety
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
December 06, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Moves Lower; AutoZone Profit Tops Views
December 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.